Hongjuan Tang – Trademark Portfolio

Entity Type: 01

Hongjuan Tang holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 8 (Hand Tools) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include CVIWE, BROBOY, and LAXTWO. The owner is based in Hunan Province.

No. 3, Group 1, Ditang Village

Zhuocao Township, Shaodong County

Hunan Province 422800 , CN

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

BROBOY
BROBOY
Registered 2025
LAXTWO
LAXTWO
Registered 2025
CVIWE
CVIWE
Registered 2020

Trademark Classifications

Hongjuan Tang's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

8
Hand Tools (1 filing)

Hand tools and implements (hand-operated); cutlery; side arms; razors

Frequently Asked Questions

How many trademarks does Hongjuan Tang have?

Hongjuan Tang has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.

What trademark classes does Hongjuan Tang file in?

Hongjuan Tang files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 8 (Hand Tools). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Hongjuan Tang's most well-known trademarks?

Hongjuan Tang's registered trademark portfolio includes well-known marks such as CVIWE, BROBOY, and LAXTWO. These are among 3 currently registered trademarks in the portfolio.

What is Hongjuan Tang's trademark registration success rate?

Hongjuan Tang has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.